← Back to Clinical Trials
Recruiting NCT05864157

NCT05864157 Targeted Motor Learning to Improve Gait for Individuals With Parkinson Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05864157
Status Recruiting
Phase
Sponsor University of North Carolina, Chapel Hill
Condition Parkinson Disease
Study Type INTERVENTIONAL
Enrollment 45 participants
Start Date 2023-08-16
Primary Completion 2026-05-01

Trial Parameters

Condition Parkinson Disease
Sponsor University of North Carolina, Chapel Hill
Study Type INTERVENTIONAL
Phase N/A
Enrollment 45
Sex ALL
Min Age 50 Years
Max Age 80 Years
Start Date 2023-08-16
Completion 2026-05-01
Interventions
Gait training without rhythmic auditory cuesTRACdTRAC

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this research study is to determine how training to step with a metronome on both a treadmill, as well as overground, will influence the way that people with Parkinson disease walk. Using metronomes is commonly used in clinics, but the investigators will be using a combination of slow and fast frequencies to alter the way that people walk. The use of a slower frequency metronome on the treadmill is intended to help participants take larger steps. The use of a faster frequency metronome while walking overground is intended to help participants take faster steps.This will take place over 12 training sessions. Each session will be about an hour. It will include some walking tests and pictures of the brain (using MRI) before and after training.

Eligibility Criteria

Inclusion Criteria: * idiopathic Parkinson's disease (Hoehn and Yahr Stage 2-3) * self-report the ability to walk uninterrupted for 10 minutes both overground and on a treadmill without therapist assistance * comfortable gait speed \> 0.4 m/s and \< 1.2 m/s * normal (or corrected to normal \[i.e., hearing aid\]) hearing * deficits in gait continuity (e.g., shuffling, shortened strides, freezing, festination, bradykinesia, etc) based on observational gait analysis * Movement Disorders Society - Unified Parkinson Disease Rating Scale (MDS-UPDRS-III) item 10 ≥1 and \<3 * be on stable doses of orally-administered levodopa * age 50-80 years old Exclusion Criteria: * contraindications to MRI (e.g., metal implants, claustrophobia, etc) * cognitive deficits (Montreal Cognitive Assessment \[MoCA\] \< 26) * concurrent Physical Therapy * have undergone deep brain stimulation surgery * cannot walk without therapist assistance * uncontrolled cardiorespiratory/metabolic disease, or other neurologica

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology